Cencora Inc. has announced the amendment and restatement of its existing Revolving Credit Facility. The updated agreement, effective as of June 4, 2025, involves Cencora and its subsidiaries, BP Pharmaceuticals Laboratories Unlimited Company and Innomar Strategies Inc., in collaboration with several lenders, including JPMorgan Chase Bank, N.A. as the administrative agent. Key changes to the facility include an increase in the total commitment to $4.5 billion and an extension of the maturity date to June 4, 2030. Additionally, certain covenants and provisions have been revised. The involved lenders and their affiliates have a history of providing various financial services to Cencora and may continue to do so in the future.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.